TLOG
vs
S&P 500
TLOG
S&P 500
Over the past 12 months, TLOG has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +13% growth.
Stocks Performance
TLOG vs S&P 500
Performance Gap
TLOG vs S&P 500
Performance By Year
TLOG vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
TetraLogic Pharmaceuticals Corp
Glance View
TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The firm's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The firm has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The firm is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
